PHILADELPHIA, November 23, 2015 — Premier Research announces the appointment of Dr. Colin Hayward, FFPM, as Chief Medical Officer. Dr. Hayward is Premier Research’s top medical expert, providing global leadership for patient safety, scientific and ethical governance, and delivery of high-quality customer service.
Dr. Hayward embodies a rare combination of business and scientific expertise. After a career in hospital medicine with a focus on anesthesia and intensive care, he entered the pharmaceutical world. Using his expertise in local medical affairs and pharmacovigilance, Dr. Hayward became International Medical Leader at Roche, developing innovative medical marketing strategies for products in supportive care, anemia, and oncology.
In 2007 he joined the board of Prism Ideas Ltd. After helping grow Prism and earning a Queen’s Award for business, he came to Premier Research in 2012, where he was the company’s Vice President of Medical Affairs, providing round-the-clock medical support to ensure that customers’ multimillion-euro drug development projects met their goals and adhered to stringent safety rules. He left Premier to serve as European Medical Director for Myriad Genetics, and returned to fill our newly created Chief Medical Officer position.
He holds a degree in medicine from Guys and St. Thomas’s Hospitals, London.
About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, and pediatric research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.